Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Exagen Diagnostics said today that it has signed up EndoChoice to promote its genomic tests for bowel disorders to gastrointestinal doctors in the US.

EndoChoice, which specializes in gastroenterology, will market Exagen's gene expression tests for diagnosing inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Albuquerque, NM-based Exagen said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

Feb
20
Sponsored by
Thermo Fisher Scientific

This webinar will discuss the use of 3’ mRNA sequencing to reduce the cost of gene expression studies on Illumina NGS systems.